Cogent Biosciences (COGT) Share-based Compensation (2017 - 2026)
Cogent Biosciences (COGT) posted quarterly Share-based Compensation of $16.9 million for Q1 2026, up 68.94% year-over-year from $10.0 million in Q1 2025, and up 1437.09% quarter-over-quarter from $1.1 million in Q4 2025.
Cogent Biosciences (COGT) Share-based Compensation (2017 - 2026) Analysis & Trends
Cogent Biosciences (COGT) has reported Share-based Compensation for 10 consecutive years, with $16.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Share-based Compensation rose 68.94% year-over-year to $16.9 million; the TTM figure through Mar 2026 stood at $38.3 million (up 6132.2% YoY), while the FY2025 annual figure was $46.1 million, up 338.85% from the prior year.
- Share-based Compensation improved to $16.9 million in Q1 2026 per COGT's latest filing, from $1.1 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $16.9 million in Q1 2026 and bottomed at -$29.8 million in Q4 2024.
- Historically, Share-based Compensation has averaged $5.4 million across 5 years, with a median of $8.8 million in 2023.
- On a YoY basis, Share-based Compensation climbed as much as 3031.0% in 2024 and fell as far as 436.27% in 2024.
- Cogent Biosciences' Share-based Compensation stood at $5.0 million in 2022, then surged by 75.72% to $8.9 million in 2023, then sank by 436.27% to -$29.8 million in 2024, then jumped by 103.7% to $1.1 million in 2025, then surged by 1437.09% to $16.9 million in 2026.
- Business Quant data shows COGT's Share-based Compensation at $16.9 million in Q1 2026, $1.1 million in Q4 2025, and $10.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Cogent Biosciences | 6.58 Bn | 6.58 Bn | - | 17.11 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 17.11 Mn |
| Jun 30, 2026 | 17.11 Mn |
| Mar 31, 2026 | 16.91 Mn |
| Mar 31, 2026 | 16.91 Mn |
| Dec 31, 2025 | 1.10 Mn |
| Dec 31, 2025 | 1.10 Mn |
| Sep 30, 2025 | 10.60 Mn |
| Sep 30, 2025 | 10.60 Mn |
| Jun 30, 2025 | 9.72 Mn |
| Jun 30, 2025 | 9.72 Mn |
| Mar 31, 2025 | 10.01 Mn |
| Mar 31, 2025 | 10.01 Mn |
| Dec 31, 2024 | -29.76 Mn |
| Dec 31, 2024 | -29.76 Mn |
| Sep 30, 2024 | 10.36 Mn |
| Sep 30, 2024 | 10.36 Mn |
| Jun 30, 2024 | 10.01 Mn |
| Jun 30, 2024 | 10.01 Mn |
| Mar 31, 2024 | 9.39 Mn |
| Mar 31, 2024 | 9.39 Mn |